Please assess the completion status of the following clinical trial:

Trial Title: Naïve HIV POC Monotherapy Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Documented chronic HIV-1 infection~* HIV-1 plasma viral load at screening visit above 5000 HIV-1 RNA copies/ml~* Male, aged above 18 years and less than 65 years of age~* Adequate method of birth control~* Subject has never received an antiretroviral agent (NRTI, NNRTI, PI, entry inhibitor or integrase inhibitor) for the treatment of HIV and agrees not to start antiretroviral therapy prior to enrollment or subject has only received a short course of treatment for less than 14 days and has been off treatment for at least 8 weeks~* Subject has no primary mutation in the reverse transcriptase (RT) gene associated with resistance to RT inhibitors and no major mutation in the protease gene associated with resistance to PIs determined by genotypic resistance testing at screening~Exclusion Criteria:~* History or suspicion of alcohol or drug abuse which in the Investigator's opinion may lead to non-compliance~* CD4 count \< 350 cells/mm3~* Life expectancy of less than 6 months~* Receipt of an investigational drug within 30 days prior to the trial drug administration~* Receipt of any vaccine within 30 days of screening visit~* Acute HIV-1 infection (seroconversion illness)~* Acute hepatitis A or acute or chronic hepatitis B or C infection~* Currently active acquired immune deficiency syndrome (AIDS)-defining illness (Category C conditions according to the Centers for Disease Control \[CDC\] Classification System for HIV Infection 1993)~* No clinically relevant laboratory abnormalities Renal impairment: serum creatinine \> 1.5 x ULN~* Febrile illness within 120 hours prior to dosing~* History of severe drug allergy or hypersensitivity~* Significant cardiac dysfunction

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- RDEA806 400 mg (Type: EXPERIMENTAL): Placebo or RDEA806 400 mg twice daily (BID) for 7 days and a single morning dose on Day 8.
- RDEA806 600 mg (Type: EXPERIMENTAL): Placebo or RDEA806 600 mg once daily (QD) for 7 days with an additional dose on the morning of Day 8.
- RDEA806 800 mg (Type: EXPERIMENTAL): Placebo or RDEA806 800 mg QD using enteric coated tablets for 7 days with an additional morning dose on Day 8.
- RDEA806 1000 mg (Type: EXPERIMENTAL): Placebo or RDEA806 1000 mg QD using enteric coated tablets for 7 days with an additional dose on the morning of Day 8.

Based on this trial design, predict the completion outcome and termination type (if applicable).